LYSA-LYSARC 2024 interactive activity report

You can view this interactive report by clicking here:

LYSA-LYSARC activity report 2024

2024 was a rich and stimulating year for the LYSA-LYSARC group, marked in particular by major scientific successes and challenges overcome collectively. This momentum was driven by the commitment of our teams and the renewed confidence of our partners.

Three highlights punctuated the year and illustrate the vitality and impact of our actions:

• The expansion into chronic lymphocytic leukaemia (CLL) and Waldenström’s macroglobulinaemia (WM) with the creation of a new LYSA commission.
• The scientific wealth showcased at the 8th LYSA conference
• The desire for innovation realised with the pioneering BIDIFLY programme

Among the scientific successes of 2024 was the launch of two major projects in follicular lymphoma:

• The use of artificial intelligence with the BIDIFLY programme
• MORNINGLYTE pivotal study in first-line treatment

These initiatives and large-scale projects made 2024 a year focused on innovation and excellence. All of these scientific successes were made possible thanks to the commitment of our teams and the renewed confidence of our partners. Building on its achievements, the LYSA-LYSARC group strives each year to carry out structural projects to consolidate its foundations and build for the future.